Literature DB >> 16507827

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Xavier Castellsagué1, Mireia Díaz, Silvia de Sanjosé, Nubia Muñoz, Rolando Herrero, Silvia Franceschi, Rosanna W Peeling, Rhoda Ashley, Jennifer S Smith, Peter J F Snijders, Chris J L M Meijer, F Xavier Bosch.   

Abstract

BACKGROUND: Most cancers of the uterine cervix are squamous cell carcinomas. Although the incidence of such carcinomas of the uterine cervix has declined over time, that of cervical adenocarcinoma has risen in recent years. The extent to which human papillomavirus (HPV) infection and cofactors may explain this differential trend is unclear.
METHODS: We pooled data from eight case-control studies of cervical cancer that were conducted on three continents. A total of 167 case patients with invasive cervical adenocarcinoma (112 with adenocarcinoma and 55 with adenosquamous carcinoma) and 1881 hospital-based control subjects were included. HPV DNA was analyzed in cervical specimens with the GP5+/6+ general primer system followed by type-specific hybridization for 33 HPV genotypes. Blood samples were analyzed for chlamydial and herpes simplex virus 2 (HSV-2) serology. Multivariable unconditional logistic regression modeling was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs). All tests of statistical significance were two-sided.
RESULTS: The adjusted overall odds ratio for cervical adenocarcinoma in HPV-positive women compared with HPV-negative women was 81.3 (95% CI = 42.0 to 157.1). HPV 16 and HPV 18 were the two most commonly detected HPV types in case patients and control subjects. These two types were present in 82% of the patients. Cofactors that showed clear statistically significant positive associations with cervical adenocarcinoma overall and among HPV-positive women included never schooling, poor hygiene, sexual behavior-related variables, long-term use of hormonal contraception, high parity, and HSV-2 seropositivity. Parity had a weaker association with adenocarcinoma and only among HPV-positive women. Use of an intrauterine device (IUD) had a statistically significant inverse association with risk of adenocarcinoma (for ever use of an IUD compared with never use, OR = .41 [95% CI = 0.18 to 0.93]). Smoking and chlamydial seropositivity were not associated with disease.
CONCLUSIONS: HPV appears to be the key risk factor for cervical adenocarcinoma. HPV testing in primary screening using current mixtures of HPV types and HPV vaccination against main HPV types should reduce the incidence of this cancer worldwide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507827     DOI: 10.1093/jnci/djj067

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  150 in total

1.  Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

Authors:  Walter Kinney; Barbara Fetterman; J Thomas Cox; Thomas Lorey; Tracy Flanagan; Philip E Castle
Journal:  Gynecol Oncol       Date:  2011-01-26       Impact factor: 5.482

2.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

3.  Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Authors:  Daniela Ehehalt; Barbara Lener; Haymo Pircher; Kerstin Dreier; Heiko Pfister; Andreas M Kaufmann; Sergio Frangini; Sigrun Ressler; Elisabeth Müller-Holzner; Markus Schmitt; Daniela Höfler; Ursula Rostek; Andreas Kaiser; Andreas Widschwendter; Werner Zwerschke; Pidder Jansen-Dürr
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

Review 4.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

5.  Profile and retrospective analysis of the use of preventive strategies in patients with cervical cancer in South-South Nigeria.

Authors:  Bassey Goddy; Nyengidiki T Kennedy; Onwubuariri Michael
Journal:  Niger Med J       Date:  2015 Mar-Apr

6.  Do you approve of spending $300 million on HPV vaccination?: yes.

Authors:  Marc Steben
Journal:  Can Fam Physician       Date:  2008-02       Impact factor: 3.275

7.  Human papillomavirus vaccine for children and adolescents.

Authors: 
Journal:  Paediatr Child Health       Date:  2007-09       Impact factor: 2.253

8.  Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine.

Authors:  Rachel Greenberg; Bruce Greenwald; J Scott Roth; Olga Ioffe; Raymond Cross
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

9.  Cervical carcinoma rates among young females in the United States.

Authors:  Vicki B Benard; Meg Watson; Philip E Castle; Mona Saraiya
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

10.  Attitudes and knowledge of Georgian physicians regarding cervical cancer prevention, 2010.

Authors:  Robert A Bednarczyk; Maia Butsashvili; George Kamkamidze; Maia Kajaia; Louise-Anne McNutt
Journal:  Int J Gynaecol Obstet       Date:  2013-03-14       Impact factor: 3.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.